hVIVO plc (LON:HVO - Get Free Report)'s stock price traded up 21.6% during trading on Monday . The company traded as high as GBX 11 ($0.15) and last traded at GBX 10.58 ($0.14). 39,171,918 shares changed hands during trading, an increase of 940% from the average session volume of 3,768,332 shares. The stock had previously closed at GBX 8.70 ($0.12).
Wall Street Analyst Weigh In
Separately, Shore Capital reaffirmed a "buy" rating on shares of hVIVO in a research report on Friday, May 30th.
Read Our Latest Research Report on HVO
hVIVO Trading Up 3.4%
The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The company has a fifty day moving average of GBX 15.92 and a 200-day moving average of GBX 17.70. The firm has a market capitalization of £76.07 million, a PE ratio of 4.43 and a beta of 0.97.
hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, sell-side analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Featured Stories
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
